• Explore /
  • Poster
  • / Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating <em>HER2</em> alterations: A phase I basket trial<sup></sup>.

Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.

Abstract Poster

Authors

Bob Li

Bob T. Li

Memorial Sloan Kettering Cancer Center, New York, NY

Bob T. Li , Tianhong Li , Melissa Lynne Johnson , Saiama Naheed Waqar , Viola Weijia Zhu , Sai-Hong Ignatius Ou , Jessica Jiyeong Lin , Ding Wang , Geoffrey Shapiro , Judy Sing-Zan Wang , Dazhi Liu , Yuqing Ye , Hana Kosar , Angela Hee , Greg Berk , Sean Zhang , Junsheng Wang , Manish R. Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02500199

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3510)

DOI

10.1200/JCO.2020.38.15_suppl.3510

Abstract #

3510

Poster Bd #

240

Abstract Disclosures

Similar Posters

First Author: Sara A. Hurvitz

First Author: Hiroya Taniguchi

First Author: Mohamed Shanshal

Poster

2023 ASCO Annual Meeting

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

First Author: Jordi Rodon Ahnert